RNS Number : 2309V
OptiBiotix Health PLC
14 August 2025

14 August 2025

OptiBiotix Health plc
("OptiBiotix" or the "Company")

Launch of SlimBiome® in leading US brand

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutesannounces the launch of a product containing its award-winning appetite reducing SlimBiome® in Hydroxycut, which markets itself as the No. 1 selling weight loss supplement brand in the United States of America ("USA").

This announcement confirms the launch of the first product under the brand name 'Hydroxycut Hunger Control', and follows on from the first orderannouncementon15 April2025.The product is sold through online outlets and retail outlets such as Walmart (as shownhere), and product marketing includes two studies carried out by OptiBiotix which demonstrate reduction in hunger of 74% and 83%. Orders for a second product application have been received and expected to be launched later this year.

Hydroxycut is America's No.1 selling weight loss supplement brand and has sold over 100 million bottles of its product over the last two decades*. Hydroxycut products are sold online and via major retail outlets across the USA such as Walmart, Kroger, Target, GNC, Kmart, Albertsons, CVS Pharmacies and more. The brand has high customer awareness and in recent years has become increasingly known for its science backed products. The introduction of SlimBiome®, with its scientifically substantiated health claims of hunger control, helps to differentiate these products from other weight management products on the market.

This news is significant for the Company as it represents the inclusion of SlimBiome® in the products of one of the USA's most popular weight management brands which has led to orders totalling just under five metric tonnes for SlimBiome® in 2025. The Board believes that the opportunity has potential for future development and will provide further updates in due course.

Stephen O'Hara, CEO of OptiBiotix, commented:"*We are pleased to announce the launch of products containing our patented award winning SlimBiome®inthe USA. The Company has been working with Hydroxycut for almost two years to carry out human studies which allows the brand to make health claims of reductions in hunger of 74% and 83% in the USA.The launch with Hydroxycut substantiates the science behind SlimBiome and helps build the SlimBiome brand in consumer markets around the world. This is another example of the Company launching products with well-known brands in key international markets which if successful, individually and collectively, havethe potential to make a significant contribution to future sales growth and shareholder value."*

**Hydroxycut: America's Best Selling Weight Loss Supplement*

The Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

For further information, please contact: OptiBiotix Health plc www.optibiotix.com
Neil Davidson, Chairman *Contact via Walbrook below*
Stephen O'Hara, Chief Executive

Cairn Financial Advisers LLP (NOMAD and Broker) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti

Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as "believe", "could", "should" "envisage", "estimate", "intend", "may", "plan", "potentially", "expect", "will" or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

PRLGZGMRKFLGKZM